The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi […]readmore
Tags : Hanmi
Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product Merck to receive an exclusive […]readmore
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Shots: Janssen has decided to return its rights of Hanmi’s HM12525A due to inability of the therapy to control blood glucose level in obese patient though the drug achieved the […]readmore